Clinical Trial Update: Study Assessing Immunogenicity and Safety of IC43 In Intensive Care Patients [Phase 2]

View source ↗

Summary

A Phase 2 study assessing immunogenicity and safety of the IC43 vaccine in intensive care patients with ventilator-associated pneumonia has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ventilator-associated Pneumonia

Drugs mentioned

• IC43

Snippet

Sponsor: Valneva Austria GmbH | Conditions: Pneumonia, Ventilator-Associated | Phase 2 | Status: COMPLETED